Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling.
Overview
Vasodilators reduce vascular smooth-muscle tone through multiple molecular targets. Their effects on venous capacitance, systemic arterial resistance and pulmonary vascular resistance differ, making a drug appropriate for one condition but harmful in another. Indications include angina, selected heart failure regimens, hypertension and specialist vascular disorders [1–3].
Classification and mechanisms
- Organic nitrates: nitroglycerin, isosorbide dinitrate and mononitrate donate bioactive nitric oxide-related species, activating soluble guanylyl cyclase and cGMP-dependent smooth muscle relaxation; venodilation often predominates at therapeutic doses.
- Direct arteriolar dilators: hydralazine reduces resistance vascular tone by incompletely characterized actions; minoxidil activates ATP-sensitive potassium channels after conversion to minoxidil sulfate.
- Calcium-channel blockers: amlodipine and nifedipine inhibit L-type calcium influx in arteries; verapamil and diltiazem also affect cardiac conduction.
- Alpha-1 antagonists: prazosin and doxazosin inhibit catecholamine-mediated vascular constriction but are not usual first-line hypertension drugs.
- Specialist drugs: sodium nitroprusside is a rapidly titratable IV arterial and venous dilator; PDE5 inhibitors, prostacyclin-pathway medicines and endothelin-receptor blockers have selected pulmonary vascular indications [1].
Evidence-based clinical use
Sublingual nitroglycerin can provide rapid relief in chronic stable angina; long-acting nitrates are symptom-control medicines and do not substitute for therapies proven to reduce cardiovascular events. Hydralazine combined with isosorbide dinitrate can improve outcomes in selected HFrEF patients and when first-line renin–angiotensin system therapies cannot be used, according to heart-failure guidance. Oral minoxidil is reserved for difficult hypertension because it often causes fluid retention and reflex tachycardia [2,3].
Pharmacokinetics and precautions
Nitroglycerin has extensive first-pass metabolism and is commonly administered sublingually or transdermally. Continuous nitrate exposure may cause tolerance, so longer-acting preparations generally need a daily low-nitrate interval. Nitroprusside infusions require intensive BP monitoring and caution for cyanide or thiocyanate accumulation, particularly with prolonged exposure or renal/hepatic impairment. Hydralazine has variable acetylation and may cause drug-induced lupus; minoxidil may cause hypertrichosis and pericardial effusion [1].
Major interactions and contraindications
Nitrates combined with sildenafil, tadalafil or other PDE5 inhibitors can cause profound hypotension; follow specific washout intervals. Nitrates should also not be combined with soluble guanylyl cyclase stimulators such as riociguat. Severe hypotension or suspected right-ventricular infarction requires caution with preload-reducing drugs. Hydralazine and minoxidil can trigger reflex tachycardia and sodium retention; combine and monitor according to specialist protocols [1–3].
Clinical takeaways
Classify each agent by molecular pathway, arterial-versus-venous effect, indication and toxicity. Do not group PDE5 inhibitors with direct nitric-oxide donors or describe endothelin antagonists as nonspecific metabolic inhibitors [1].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC multisociety guideline for chronic coronary disease. Circulation. 2023;148:e9–e119. Available from: https://professional.heart.org/en/science-news/2023-guideline-for-the-management-of-patients-with-chronic-coronary-disease/top-things-to-know
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for management of heart failure. Circulation. 2022;145:e895–e1032. Available from: https://www.jacc.org/doi/full/10.1016/j.jacc.2021.12.012
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.